PharmaPoint: Hemophilia A and B - France Drug Forecast and Market Analysis to 2022, New Report Launched

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

The primary research indicates that the high annual cost of therapy in France is of great concern among French physicians and regulators and therefore the opportunities for premium pricing for new therapies will be limited during the forecast period. GlobalData believes that the clinical benefits offered by the emerging long-acting replacement factors will be sufficient to allow companies to negotiate modest price premiums for the long-acting therapies.

Scope

• Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

• Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.

• Sales forecast for the top drugs in France from 2012-2022.

• Analysis of the impact of key events as well the drivers and restraints affecting France Hemophilia A and B market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return

• Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B

• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

• Make more informed business decisions from insightful and in-depth analysis of drug performance

• Obtain sales forecast for drugs from 2012-2022 in France

Spanning over 137 pages, 52 Tables and 3 Figures, “PharmaPoint: Hemophilia A and B - France Drug Forecast and Market Analysis to 2022” report covering Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-hemophilia-and-b-france-drug-forecast-and-market-analysis-2022

Browse more Diseases Reports at: http://www.marketresearchreports.com/diseases